Top 10: Takeda's late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
If you’re looking for some solid reasons for Takeda CEO Christophe Weber’s relentless pursuit of a $62 billion Shire buyout, you need look no further than the Japan-based company’s Q2 numbers.
Takeda just posted its weakest second quarter numbers in three years, with profits down by half. And analysts are not happy with Takeda’s late-stage pipeline. So how does it make up for its poor R&D performance?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.